Justin Watts, Md

This phase 2 trial is testing a combination of three drugs—olutasidenib, venetoclax, and azacitidine—in adults aged 18-75 with newly diagnosed acute myeloid leukemia that has a specific IDH1 gene mutation. The study aims to see if this combo is safer and works better than standar…